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Lysosomal storage diseases (LSDs) include approximately 70 distinct disorders that
collectively account for 14% of all inherited metabolic diseases. LSDs are caused by
mutations in various enzymes/proteins that disrupt lysosomal function, which impairs
macromolecule degradation following endosome-lysosome and phagosome-lysosome
fusion and autophagy, ultimately disrupting cellular homeostasis. LSDs are pathologically
typified by lysosomal inclusions composed of a heterogeneous mixture of various
proteins and lipids that can be found throughout the body. However, in many cases the
CNS is dramatically affected, which may result from heightened neuronal vulnerability
based on their post-mitotic state. Besides intrinsic neuronal defects, another emerging
factor common to many LSDs is neuroinflammation, which may negatively impact
neuronal survival and contribute to neurodegeneration. Microglial and astrocyte activation
is a hallmark of many LSDs that affect the CNS, which often precedes and predicts
regions where eventual neuron loss will occur. However, the timing, intensity, and
duration of neuroinflammation may ultimately dictate the impact on CNS homeostasis.
For example, a transient inflammatory response following CNS insult/injury can be
neuroprotective, as glial cells attempt to remove the insult and provide trophic support
to neurons. However, chronic inflammation, as seen in several LSDs, can promote
neurodegeneration by creating a neurotoxic environment due to elevated levels of
cytokines, chemokines, and pro-apoptotic molecules. Although neuroinflammation has
been reported in several LSDs, the cellular basis andmechanisms responsible for eliciting
neuroinflammatory pathways are just beginning to be defined. This review highlights the
role of neuroinflammation in select LSDs and its potential contribution to neuron loss.
Keywords: neuroinflammation, lysosomal storage disease, microglia, astrocytes, danger-associated molecular
patterns
INTRODUCTION: LYSOSOMAL STORAGE DISEASES
Since the discovery of the lysosome nearly 60 years ago by de Duve (1969), the field of lysosomal
storage diseases (LSDs) has expanded significantly. LSDs currently encompass approximately 70
genetically distinct diseases, with a collective incidence of 1:5000 live births annually (Vitner
et al., 2015). LSDs account for roughly 14% of all inherited metabolic diseases (Meikle et al.,
1999; Wolf et al., 2015), among which the majority are autosomal recessive with the exception
of mucopolysaccharidosis type II (MPS II) being inherited as an X-linked recessive trait (Meikle
et al., 1999). A common denominator across all LSDs is lysosomal dysfunction originating from
the loss of function or expression of lysosomal enzymes or other proteins that are vital for
lysosomal homeostasis (Alroy et al., 2014). While the function of mutated molecules in some LSDs
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is well-characterized, in others, such as Niemann-Pick type C
(NPC) and Juvenile Neuronal Ceroid Lipofuscinosis (JNCL), the
normal function of mutated proteins is unknown (Baudry et al.,
2003; Kollmann et al., 2013; Vitner et al., 2015). Nevertheless,
studies using mouse models and cells from affected patients,
as well as lower species when available (i.e., yeast, Drosophila),
have provided valuable information concerning the downstream
sequelae of LSDs where the putative function of mutated
molecules remains to be identified (Pearce et al., 1999; Persaud-
Sawin et al., 2002; Huang et al., 2005; Park et al., 2008; Tuxworth
et al., 2011; Cotman and Staropoli, 2012).
Lysosomes are membrane bound organelles that are not only
responsible for macromolecule degradation but also play a role in
multiple processes required for cellular homeostasis (Appelqvist
et al., 2013). This includes phagocytosis, autophagy, apoptosis,
signal transduction, exocytosis, and inflammatory responses
(Boustany, 2013; Alroy et al., 2014) and lysosomes harbor over 60
different enzymes responsible for lipid and protein degradation
and recycling (Alroy et al., 2014). Lysosomal inclusion formation
is a hallmark of LSDs, where the composition of inclusions can
vary widely depending on the type of mutation to include a
heterogeneous combination of sphingolipids, phospholipids, or
galactosylceramide as well as proteins (Ballabio and Gieselmann,
2009). In general, most LSDs are typified by inclusions in both
the CNS and periphery, since affected proteins are generally
universally expressed in the lysosomes of all cells. Nevertheless,
it is evident that the CNS is extremely vulnerable to impaired
lysosomal function and as such, numerous LSDs are associated
with neurological sequalae. LSDs are often characterized into
four subgroups based on the composition of lipid accumulation,
namely, mucopolysaccharidoses, glycolipidoses, mucolipidoses,
and glycoproteinoses (Futerman and van Meer, 2004; Alroy
et al., 2014). These glycolipids and glycoproteins comprise the
main structural components of cell membranes and influence
cellular trafficking, second messenger signaling, and cell-cell
communication (Cooper, 2000; Farooqui, 2009). Therefore,
perturbations in membrane lipid recycling or breakdown
consequently lead to disruptions in myelin production,
molecular transport systems, apoptosis, and immune system
activation (Alroy et al., 2014).
Several LSDs exhibit neuropathological manifestations,
including prominent microglial and astrocyte activation (Baudry
et al., 2003; Farfel-Becker et al., 2011; Wilkinson et al., 2012;
Kollmann et al., 2013). The functional implications of reactive
glia in LSD progression remains unclear and can be envisioned
to be either a protective response to cellular stress or detrimental,
leading to the loss of critical CNS homeostatic functions. Several
LSDs affecting the CNS are typified by neuroinflammation,
which likely contributes to the neurodegenerative process (Cox
and Cachon-Gonzalez, 2012; Rama Rao and Kielian, 2015).
However, it remains unclear whether inflammatory responses
are an inciting event or merely a consequence of sensing
danger-associated molecular patterns (DAMPs) released from
damaged/dying cells (Thundyil and Lim, 2014). This review will
provide a brief overview of general aspects of neuroinflammatory
paradigms in LSDs and focus on converging and diverging
aspects of neuroinflammation in four LSDs with prominent
CNS manifestations namely, NPC, Gaucher Disease (GD),
Mucopolysaccharidoses (MPS), and the group of Neuronal
Ceroid Lipofusinosis (NCL), commonly referred to as Batten
Disease. Other LSDs that are typified by inflammation are briefly
discussed at the conclusion, with pertinent works cited for
further reading.
NEUROINFLAMMATION IN LYSOSOMAL
STORAGE DISEASES
Neuroinflammation is typically elicited as a protective response
following CNS injury, infection, or disease; however, heightened
or chronic inflammation can exert detrimental effects on neural
cells (Fernandes-Alnemri et al., 2009; Lyman et al., 2014; Lee
and MacLean, 2015). Inflammatory events are initiated in the
CNS upon sensing DAMPs or pathogen-associated molecular
patterns (PAMPs) by resident microglia and astrocytes, often
leading to the mobilization of peripheral leukocytes into the
CNS. The goal is a swift response to contain the insult, which
is rapidly downregulated to avoid unnecessary bystander damage
(Lyman et al., 2014). This process is facilitated by several factors,
including inflammatory cytokines and chemokines, trophic
factors, phagocytosis, and regulated forms of cell death (i.e.,
apoptosis or pyroptosis) (Bergsbaken et al., 2009; Lyman et al.,
2014; Heneka et al., 2015). However, persistent inflammation can
elicit additional damage, further perpetuating the inflammatory
cycle and CNS pathology.
Microglia are the principal neuroinflammatory cells in the
CNS parenchyma, which constantly survey for stress signals
(i.e., DAMPs), phagocytose cellular debris, and provide trophic
support (Rock et al., 2004; Heneka et al., 2015). Microglia sense
DAMPs released from damaged or dying neurons (Thundyil and
Lim, 2014) via Toll-like receptors and other pattern recognition
receptors (Hanke and Kielian, 2011; Lyman et al., 2014). Once
activated, microglia are a major source of chemokines and
cytokines that serve to recruit and activate peripheral immune
cells at affected sites, respectively (Amor et al., 2014). In
addition, these mediators can act in an autocrine/paracrine
manner to activate neighboring microglia, astrocytes, neurons,
or oligodendrocytes. The consequences of cytokine action
vary between each cell type and can include perpetuating
inflammatory mediator release, altering target cell function, or
inducing cell death (Vezzani and Viviani, 2015).
Astrocytes are the most abundant cell type in the brain and
provide neurotrophic support, synchronize neurotransmitter
metabolism and release, and regulate the extracellular
milieu (Haydon and Nedergaard, 2015; Verkhratsky et al.,
2015; Verkhratsky and Parpura, 2015). Besides these
critical homeostatic functions, astrocytes also participate in
neuroinflammatory responses through their robust secretion of
various chemokines (Dong and Benveniste, 2001; Farina et al.,
2007). Upon activation, astrocytes undergo a morphological
transformation typified by increased intermediate filament
expression (i.e., glial fibrillary acidic protein (GFAP) and
vimentin) and reactive astrocytes have been implicated in
the pathogenesis of various neurodegenerative diseases (van
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der Hel et al., 2005; Kulijewicz-Nawrot et al., 2013; Assous
et al., 2014). For example, activated astrocytes can produce
chemokines, reactive oxygen/nitrogen species, and various toxic
molecules. In addition, astrocyte activation often compromises
glutamate homeostatic pathways, such as glutamate uptake and
recycling mediated by glutamate transporters and glutamine
synthetase, respectively (Kulijewicz-Nawrot et al., 2013; Heneka
et al., 2015). Reactive astrocytes have been detected during the
acute phase of disease in animal models of Alzheimer’s Disease
(AD), Parkinson’s Disease (PD), and several LSDs, likely setting
the stage for neuronal dysfunction and neurodegeneration
(DiRosario et al., 2009; Farfel-Becker et al., 2011; Heneka
et al., 2015; Lee and MacLean, 2015). In response to insult
or injury, reactive astrocytes have been shown to provide a
bordering function to isolate areas of damage by forming a
“glial scar” that prevents dying cells from impacting healthy
tissue. Neuroinflammation also elicits astrocyte hemichannel
opening concomitant with reduced gap junction activity, which
together can significantly disrupt neurotransmitter regulation
(Karpuk et al., 2011; Orellana et al., 2011). However, chronic
neuroinflammation can also impair astrocyte neurotrophic
support, making neurons more vulnerable to cytotoxic events
(Lee and MacLean, 2015).
Neuroinflammation has been reported in several
LSDs, although the intensity of inflammatory changes
and the molecular pathways responsible for triggering
neuroinflammation in each likely differ. Although LSDs are
caused by distinct genetic mutations they share some common
downstream attributes, the foremost being lysosomal storage
material accumulation. While the biochemical composition
of storage material differs between various LSDs, emerging
evidence suggests that it can either activate or perpetuate
neuroinflammation, which can contribute to neuronal
death (Platt et al., 2012). Indeed, recent studies report that
an imbalance between the synthesis and degradation of
sphingolipid intermediates plays a prominent role in eliciting
neuroinflammatory outcomes (Nixon, 2009). For example,
TNF-α can activate sphingomyelinase (SMase), a key enzyme
responsible for ceramide production, which leads to elevated
ceramide levels that have been reported in JNCL (Puranam
et al., 1997; Mencarelli and Martinez-Martinez, 2013). It is
well appreciated that high ceramide concentrations can also
perpetuate inflammatory cascades such as NF-κB activation,
trigger inflammasome activation, and disrupt normal cellular
functions (Nixon, 2009; Mencarelli and Martinez-Martinez,
2013). Ceramide accumulation correlates with decreases in
sphinosine-1-phosphate (S1P), thereby inducing apoptotic
pathways and glial activation (Nixon, 2009). The S1P antagonist
FTY720 has been shown to attenuate glial activation and
neuroinflammatory processes, which leads to reduced relapse
rates in multiple sclerosis (Davies et al., 2013; Brunkhorst et al.,
2014), although its effects in LSDs remain to be investigated.
Glucosylceramide accumulation in Gaucher disease (GD),
resulting from glucocerebrosidase deficiency, has been shown to
augment cytokine production in microglia (Hong et al., 2006).
Likewise, glucocerebrosidase loss in a mouse neuropathy model
of GD causes microglial activation as early as postnatal day
12 (Farfel-Becker et al., 2011). The loss of lysosomal function
coupled with lipid inclusion formation disrupts lysosomal
membrane integrity, resulting in increased permeability
and translocation of lysosomal contents into the cytosol
(Pereira et al., 2010). For example, defective lysosomes release
hydrolases, metabolites, and cathepsins into the cytoplasm
that can be sensed as intracellular DAMPs (Futerman and
van Meer, 2004). Cathepsins, in particular cathepsin B, have
been shown to trigger NLRP3 inflammasome activation that
contributes to neuroinflammation as well as induces neuronal
apoptosis (Tschopp and Schroder, 2010). Additional intracellular
changes that have been reported in various LSDs also have
the ability to trigger and/or propagate neuroinflammation.
For example, several LSDs display elevated intracellular Ca2+
levels (Vitner et al., 2010; Boustany, 2013) and disruption of
Ca2+ homeostasis can induce multiple inflammatory processes
in many CNS cell types (Zundorf and Reiser, 2011). In the
case of microglia, elevated Ca2+i can induce inflammasome
activity, cytokine release, and NF-κB activation. In neurons,
increased Ca2+i disrupts synchronized synaptic activity, and
dysregulated neuronal firing can augment glutamate and ATP
release as well as other “danger” signals that, in turn, trigger
Ca2+i elevations in surrounding glia (Sama and Norris, 2013),
effectively perpetuating the response. In addition, storage
material accumulation in LSDs disrupts normal ER function
and causes ER stress, eliciting an unfolded protein response
(UPR), a physiological reaction that halts protein synthesis
in an effort to correct disrupted protein folding. However, a
persistent UPR induces apoptosis by activating various signaling
cascades, which can have catastrophic effects on the CNS
(Bronson et al., 1993; Doyle et al., 2011; Vitner and Futerman,
2013). Besides inducing cell death, ER stress can also trigger
intracellular proinflammatory processes (Salminen et al., 2009).
For example, Ca2+ released from intracellular stores leads to
NF-κB activation and subsequent cytokine, chemokine, and ROS
production, which can exacerbate neuropathology (Pahl and
Baeuerle, 1997; Salminen et al., 2009). Additionally, ER stress in
astrocytes can trigger the activation of surrounding microglia,
leading to increased IL-6 production (Meares et al., 2014).
Neuroinflammation is an overarching theme in several LSDs that
may propagate neurodegeneration. The following sections will
discuss neuroinflammatory events in select LSDs and the impact
of neuroinflammation on neuron loss in these disorders.
NIEMANN-PICK TYPE C (NPC)
Described in the late 1920s by Albert Niemann and Ludwig Pick,
NPC is caused by a mutation in either NPC1 (95% incidence)
or NPC2 (5% incidence), which manifest as similar disorders
(Williams et al., 2014; Alobaidy, 2015). The frequency of NPC has
been estimated at 1:120,000 live births annually (Alobaidy, 2015).
There are four age-dependent variants of NPC namely, infantile,
late infantile, juvenile, and adult. The infantile and late infantile
forms are most severe and occur between 2 months to 6 years
of age and are typified by cerebellar ataxia, dementia, cognitive
decline, seizures, and premature death (Vanier, 2010). NPC1
encodes for a lysosomal/endosomal transmembrane protein of
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unknown function, while NPC2 produces a soluble mannose-
6-phosphorylated lysosomal transport protein (Williams et al.,
2014). Both NPC1 and NPC2 regulate the intracellular trafficking
and processing of cholesterol and other lipids (Baudry et al., 2003;
Gallala et al., 2011). Mutation in either NPC1 or NPC2 results
in the lysosomal accumulation of cholesterol and sphingolipids,
in particular glycosphingolipids and sphingomyelin (Rosenbaum
andMaxfield, 2011). The pathogenic mechanisms responsible for
NPC disease remain to be identified.
Microglial activation has been shown to occur early in
NPC−/− mice and precedes neurodegeneration. Multiple brain
regions in NPC −/− mice display increased levels of TNF-α and
IL-1β as well as heightened apoptosis. These areas correspond
to brain regions with profound neuron loss at later stages of
the disease (Wang et al., 2010; Peake et al., 2011). Baudry et al.
found that microglial activation was significantly increased in the
striatum, thalamus, substantia nigra pars compacta, neocortex,
and cerebellum of NPC −/− mice beginning as early as postnatal
week 2 (Baudry et al., 2003). Areas of microglial activation
correlated with the onset of axonal damage by postnatal week 4
and by week 10, almost all Purkinje cells within the cerebellum
were lost (Baudry et al., 2003). Neuronal deterioration in NPC
has a specific spatial and temporal configuration, beginning with
proximal sensory and motor projection loss followed by neuron
soma dropout (Pressey et al., 2012; Vitner et al., 2015). Compared
to microglia, astrocyte activation is delayed in NPC until 4–10
weeks of age and is likely elicited in response to neuronal damage.
It has been suggested that astrocyte and microglial activation
in NPC is a protective event designed to phagocytose damaged
neurons to limit subsequent DAMP release (Minghetti and Levi,
1998; Baudry et al., 2003). However, whether neuronal death that
occurs during NPC is cell-autonomous or non-cell autonomous
is not completely understood (Baudry et al., 2003; Peake et al.,
2011).
Neuroinflammation has been suggested to play an important
role in NPC, since several studies have shown that disease
progression can be delayed with anti-inflammatory compounds
(Smith et al., 2009; Williams et al., 2014). Specifically,
treatment with non-steroidal anti-inflammatory drugs (NSAIDs)
in combination with miglustat and the antioxidant curcumin
has been shown to reduce microglial activation and Purkinje
cell death, effectively extending the survival of NPC−/− mice
(Williams et al., 2014). Recent studies have shown that
directly targeting cholesterol accumulation can also reduce
neurological damage and slow NPC progression. Specifically,
2-hydroxypropyl-β-cylodextrin (HPβCD) reduced cholesterol
and ganglioside accumulation in the cerebellum and enhanced
Purkinje cell survival, which resulted in increased life span in
both mouse and feline NPC models (Camargo et al., 2001; Vite
et al., 2015). HPβCD also reduced CD68 (microglia/macrophage)
and GFAP (astrocyte) expression in the brains of NPC−/−
mice following a 10 week treatment period (Alam et al., 2014).
These studies strongly suggest that neuroinflammation is a
major factor in NPC progression and support the concept that
targeting neuroinflammation may potentially extend the lives of
patients with NPC, although this possibility remains speculative
at the present time. Due to the multifaceted nature of NPC,
a combinational therapy targeting inappropriate inflammation
along with reversing cholesterol accumulation will likely be
required to maximally impact disease progression. This approach
is also likely necessary for other LSDs that have additional
pathological sequelae besides lysosomal storage accumulation.
GAUCHER DISEASE (GD)
Gaucher disease (GD) is the most common LSD arising
from a mutation in the lysosomal enzyme glucosylceramidase
(GlcCerase), which causes a decrease or complete loss of
enzymatic activity and intracellular glucosylceramide (GlcCer)
accumulation. The incidence of GD is 1 out of every 40,000–
60,000 live births a year and is classified into three age-dependent
forms. Type 1 is the most common (90% of patients) and
is typified by splenomegaly, hepatomegaly, anemia, bone pain,
and skeletal lesions (Vitner and Futerman, 2013). Type I GD
is not associated with any neurological symptoms, whereas
Types 2 and 3 display prominent neuropathology. Type 2 GD
is extremely rare and manifests around 6 months of age with
a life expectancy of 2–4 years, whereas Type 3 presents with
similar neurological abnormalities as Type 2 but at a later
interval in young adolescence (Sidransky et al., 1996; Vitner and
Futerman, 2013). The relationship between GlcCer accumulation
and progression of neuropathological sequelae in GD is not
completely understood (Vitner and Futerman, 2013).
GD Types 2 and 3 have been linked to elevated
proinflammatory cytokine (IL-1α, IL-1β, TNF-α, IL-6) and
reactive oxygen species (ROS) production in the brains of gba
null mice and blood of GD patients (Barak et al., 1999; Hong
et al., 2006; Vitner and Futerman, 2013). GlcCer accumulation
within inflammatory cells, macrophages and natural killer
cells in particular, impairs cell migration, antigen presentation,
and killing functions that contribute to persistent and altered
inflammatory responses in GD (Bettman et al., 2015; Nair et al.,
2015). Early studies examining the impact of neuroinflammation
on GD progression were limited by the fact that the gba
knockout (KO) mouse model has an exceptionally short life
span of 1 day (Tybulewicz et al., 1992). Recently, Enquist
et al. created a Gbaflox/flox nestin-Cre mouse that deletes
GlcCerase in neural progenitor cells that give rise to astrocytes
and oligodendrocytes, leaving the enzyme fully functional in
microglia which are derived from the yolk sac (Alliot et al.,
1999; Enquist et al., 2007). These studies revealed the early
synthesis of anti-inflammatory cytokines, which later shifted
to a pro-inflammatory phenotype (Enquist et al., 2007; Vitner
et al., 2012), suggesting that neuroinflammation may be elicited
by DAMPs released from diseased neurons, astrocytes, and/or
oligodendrocytes. By extension, these DAMPs are expected to
trigger robust microglial proinflammatory activity, culminating
in a neurotoxic environment that promotes neurodegeneration.
In addition, studies have shown that GlcCer accumulation is
linked to disrupted Ca2+ homeostasis in neurons, where GlcCer
interacts with the ryanodine receptor, which is responsible for
ER Ca2+ release (Korkotian et al., 1999; Vitner and Futerman,
2013). Elevated Ca2+i levels in neurons increases sensitivity to
neurotoxic agents and induces DAMP release (Sama and Norris,
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2013). Unfortunately, anti-inflammatory compounds have had
no effect on prolonging survival of Gba−/− mice (Vitner et al.,
2012). These findings suggest that neuronal loss may primarily
be cell-autonomous and that therapeutic targeting should be
more focused on the contribution of neurons to inflammatory
reactions.
MUCPOLYSACCHARIDOSIS (MPS)
MPS encompasses a heterogeneous group of LSDs that result
from a deficiency in lysosomal enzymes responsible for
glycosaminoglycan (GAG) degradation (Wraith, 1995; Archer
et al., 2014). MPS forms represent about 30% of all LSDs, with
an incidence in 1 out of every 25,000 births (2011). Clinical
symptoms typically present early in life with either severe or
attenuated phenotypes (Muenzer, 2004). Patients can experience
neurodegeneration, behavioral deficits, such as hyperactivity
and aggressiveness, and peripheral organ dysfunction (Archer
et al., 2014). MPS forms are caused by a mutation in any one
of 11 distinct hydrolases that function in GAG degradation
(Alroy et al., 2014). The loss of catabolic function causes an
accumulation of heparan sulfate (HS) and dermatan sulfate in
lysosomes followed by subsequent ganglioside accumulation in
the CNS, similar to what is found in GM-gangliosidosis (Archer
et al., 2014). Ganglioside accumulation has been shown to disrupt
lysosomal function, leading to multi-organ failure and death
(Archer et al., 2014).
Astrocyte and microglial activation has been suggested to
impact MPS pathogenesis (Campos and Monaga, 2012; Archer
et al., 2014). As storage material accumulates within the
lysosome it can disrupt lysosomal membrane integrity, leading
to lysosomal membrane permeability and subsequent release
of HS, gangliosides, and cysteine proteases into the cytoplasm
(Pereira et al., 2010). In turn, these molecules can act as
intracellular DAMPs to perpetuate microglial activation and
promote inflammatory responses (Campos and Monaga, 2012).
An alternative possibility is that HS directly activates Toll-like
receptor 4 (TLR4) that elicits pro-inflammatory cytokine and
reactive oxygen species (ROS) production to perpetuate the
inflammatory process. However, in this instance, HS would need
to be released into the extracellular milieu to engage TLR4, which
appears only plausible via cell death or lysosomal exocytosis.
Nevertheless, inflammatory responses elicited by the release of
various DAMPs from cellular injury likely contribute to the
neurodegenerative process in MPS.
Besides microglial responses, another important factor
contributing to inflammation in MPS is peripheral immune
system activation (DiRosario et al., 2009). In multiple models
of MPS (MPS I, IIIA, IIIB) numerous chemokines are elevated
in the brain, including CCL3 and CCL4, which correlate with
peripheral T cell and macrophage infiltrates (Villani et al., 2007;
Arfi et al., 2011). Additionally, treatment of MPS IIIA mice
with acetylsalicylic acid over a 6 month period significantly
attenuated cytokine and chemokine expression, apoptosis-related
genes, and increased the antioxidant status of the brain as
demonstrated by increased glutathione levels (Arfi et al.,
2011). Another report demonstrated that immunosuppression
with prednisolone significantly slowed CNS disease progression
in a mouse model of MPS IIIB (DiRosario et al., 2009).
Collectively, these findings suggest that anti-inflammatory drugs
dampen neuroinflammation and could potentially improve
disease outcome in specific MPS forms (Arfi et al., 2011).
NEURONAL CEROID LIPOFUSCINOSIS
(NCL)
NCLs are a diverse group of autosomal recessively inherited LSDs
caused by a mutation in one of 14 different ceroid lipofuscinosis
(CLN) genes (Kollmann et al., 2013). NCLs have been estimated
to occur in 1 out of every 100,000 live births per year (Lerner et al.,
1995; Jalanko and Braulke, 2009; Santorelli et al., 2013). There
are four age-dependent classifications of NCL that correlate with
specific genetic mutations; namely, infantile (INCL), late infantile
(LINCL), juvenile (JNCL), and adult onset (Cooper, 2003).
The four subtypes generally present with similar symptoms
that include visual deterioration, neurocognitive and physical
decline, seizures, and premature death, although the sequence
of symptom appearance differs between forms (Mitchison et al.,
2004; Finn et al., 2011; Cotman and Staropoli, 2012; Anderson
et al., 2013). The early onset NCLs, including infantile and
late infantile, are the most aggressive in terms of the short
interval from diagnosis to death and are generally typified by
more prominent neuroinflammatory responses (Dolisca et al.,
2013). The various NCL-related mutations result in either a
loss in lysosomal enzymes, lysosomal transmembrane proteins,
or synaptic vesicle-associated proteins (Kollmann et al., 2013).
Although the function of some NCL-related genes are known
(i.e., CLN1 and CLN2 encode for the lysosomal enzymes
PPT-1 and TPP-1, respectively), others remain elusive (i.e.,
CLN3, CLN5, CLN6). Mutations in each of the CLN proteins
lead to the accumulation of lysosomal storage material whose
biochemical composition varies according to each disease type.
For example, storage material can contain mitochondrial ATP
synthase subunit c, sphingolipids, and lipofuscin, the latter of
which is responsible for the autofluorescent properties of storage
material (Haltia, 2003; Williams et al., 2006). To date there is no
cure for any of the NCL forms, only treatments tomanage clinical
symptoms.
Emerging evidence suggests that neuroinflammation may
play a role in NCL pathogenesis, although the timing and
intensity of inflammatory events in each disease type likely
differ. For example, neuroinflammation is robust in the most
aggressive form of NCL (INCL), where glial activation parallels
increased proinflammatory cytokine production and peripheral
immune cell infiltration into the brain (Macauley et al., 2012).
Microglial and astrocyte activation has also been shown to
precede neuronal death in affected brain regions in JNCL
(Pontikis et al., 2004). Primary microglia isolated from CLN3
mutant (CLN31ex7/8) mice exist in a primed pro-inflammatory
state (Xiong and Kielian, 2013), producing heightened levels of
numerous mediators, including TNF-α, IL-9, IL-1β, IL-1α, IL-15,
and IL-10 following exposure to DAMPs elevated in the JNCL
brain (Puranam et al., 1997; Mencarelli and Martinez-Martinez,
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2013). As mentioned above, the degree of neuroinflammation
in the various NCL forms appears to correlate with the
severity of disease progression. For example, INCL and LINCL,
which are more aggressive in their clinical course compared to
JNCL (Hawkins-Salsbury et al., 2013), display more rampant
neuroinflammation (Palmer et al., 2013). This could be explained
by the compressed time frame of disease typified by extensive and
rapid neuronal death (Kielar et al., 2007). This would effectively
increase DAMP release and trigger early glial activation that
would impact neuronal function in a non-cell autonomous
manner, causing direct inflammatory damage and loss of trophic
support, which would further exacerbate neuronal death in a
vicious feedback loop (Figure 1). In fact, multiple NCL forms
are typified by synaptic loss coupled with an imbalance in
critical neurotransmitter functions (Palmer et al., 2013). For
example, patients with CLN1, CLN2, and CLN6 mutations
exhibit decreased GABA and glutamate levels, while individuals
with CLN3 mutations have excessive glutamate and lower GABA
in the CNS (Sitter et al., 2004; Pears et al., 2005, 2007). The
reasons responsible for differential neurotransmitter dysfunction
between various NCL forms are not understood; however, it is
clear that neurotransmitter imbalances likely exacerbate defects
in neuronal function that are observed in these diseases. In
addition, loss of microglial and astrocyte homeostatic functions
increases neuron vulnerability to not only toxic inflammatory
molecules but also insults from surrounding neurons, such as
neurotransmitter excitotoxicity (Hachiya et al., 2006). A role for
neuroinflammation in NCL progression is only beginning to be
mechanistically explored, with a recent study showing beneficial
effects of anti-inflammatory treatments (Macauley et al., 2012).
For example, Macauley et al. found that a combination of anti-
inflammatory compounds increased the survival rate of Ppt1−/−
mice, a model of INCL, concomitant with reduced cytokine
production and less regional brain atrophy. This study suggests
that anti-inflammatory treatment can be beneficial in slowing
neurodegeneration caused by inflammatory insults (Macauley
et al., 2012); however, it remains to be determined whether these
compounds exert their beneficial effects by limiting inflammation
or rather, also impact other disease attributes of neurons and glia.
NFLAMMATION IN OTHER LYSOSOMAL
STORAGE DISEASES
In addition to the LSDs described in detail above, there is
emerging evidence implicating neuroinflammation in other
LSDs, including Tay-Sachs, Sandhoff disease, and Fabry disease.
Tay-Sachs and Sandhoff disease are both GM2 gangliosidoses,
typified by ganglioside accumulation throughout the CNS
(Jeyakumar et al., 2003). The mechanisms responsible for disease
progression and cell death in these LSDs remains unknown;
however, murine models and patient samples suggest a role for
FIGURE 1 | Potential vicious cycle that perpetuates neuronal loss during lysosomal storage diseases (LSDs). 1. Neuroinflammation associated with LSDs
may be initiated, in part, by the disruption of normal lysosomal function and accumulation of heterogeneous inclusions. 2. Lysosome dysfunction triggers the activation
and/or release of danger associated molecular patterns (DAMPs). 3. DAMPs activate surrounding glial cells, resulting in their proliferation and initiating inflammatory
signaling pathways. 4. Activated glia produce chemokines, cytokines, and other inflammatory mediators (i.e., reactive oxygen/nitrogen intermediates). 5. The cytotoxic
environment and loss of glial support results in neuron death and DAMP release, which further perpetuates the neuroinflammatory cycle.
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inflammation. Neuroinflammation has been found to precede
symptom onset in mouse models of Tay-Sachs and Sandhoff
disease (Jeyakumar et al., 2003). In addition, inflammatory
mediators are elevated in patients with Tay-Sachs or infantile
gangliosidosis, including MCP-1α, MIP-1β, and TNFR2, and the
intensity of inflammation is heightened in the more aggressive
infantile forms compared to the juvenile forms (Hayase et al.,
2010; Utz et al., 2015). This pattern is similar to what has
been reported in multiple LSDs (Pahl and Baeuerle, 1997;
Vanier, 2010; Hawkins-Salsbury et al., 2013). Fabry disease is
the second most common LSD and results from a reduction or
loss of α-galactosidase A, leading to the accumulation of neutral
glycosphingolipids (Meikle et al., 1999; Mauhin et al., 2015).
Patients with Fabry disease have elevated levels of IL-6, IL-1β,
and TNF-α in the systemic circulation, revealing an inflammatory
aspect of this LSD (De Francesco et al., 2013; Mauhin et al., 2015).
When taken together, neuroinflammation has been implicated as
a pathological hallmark of a wide range LSDs, suggesting it may
be a viable target when considering potential new therapeutics.
OUTSTANDING QUESTIONS AND FUTURE
RESEARCH AVENUES
Although our understanding of LSDs has significantly expanded
since the discovery of the lysosome by DeDuve in the 1950s,
many questions remain unanswered. There is currently no
cure for any of the LSDs mentioned and the only available
therapeutics target disease symptoms. Therefore, it is imperative
to identify novel therapeutics to not only alleviate symptoms
but also slow disease progression and extend life expectancy.
The genetic mutations unique to each LSD result in distinct
malfunctions of a specific lysosomal mechanism. By extension,
this would suggest that each disease would present with different
symptoms, neuropathology, and disease progression. However,
many similarities exist between these attributes among the
diverse array of LSDs, which suggests the possibility of unifying
mechanisms of downstream pathology. If accurate, in-depth
comparisons of the similarities and differences between LSDs
have the potential to direct researchers toward overarching
mechanistic pathways to target for treatment.
One of the main attributes shared across several LSDs
is neuropathological symptoms, such as seizures and
neurocognitive decline, leading to premature death (Muenzer,
2004; Lim et al., 2006; Vanier, 2010; Anderson et al., 2013;
Vitner and Futerman, 2013). Substrate accumulation within
the lysosomes of neurons is expected to disrupt their normal
homeostatic functions, although it is clear that the presence
of inclusion material per se is not a requisite for death, since
only neurons in specific brain regions are lost in several
LSDs (Cotman et al., 2002; Baudry et al., 2003; Muenzer,
2004). Impaired neuronal function can augment glutamate
and ATP release, which can be sensed by surrounding
glia as danger signals triggering their activation to clear
senescent/damaged cells or debris in an attempt to restore
homeostasis, along with offering trophic support to surrounding
neurons. Glial cells also produce trophic factors, such as TGF-β
and matricellular proteins in an effort to halt damage and
promote neuronal survival and health (Dheen et al., 2007);
however, sustained DAMP release can result in chronic
pathological inflammation. A role for inflammation is
supported by the increase in glial activation that precedes
neurodegenerative changes in NPC, GD, MPS, and NCLs
(Baudry et al., 2003; Pontikis et al., 2004; Farfel-Becker et al.,
2011; Archer et al., 2014) and the positive outcomes of anti-
inflammatory therapies on extending the survival of NPC
and MPS mouse models (Arfi et al., 2011; Williams et al.,
2014).
There is a strong correlation between neuroinflammation and
disease progression in several LSDs; however it is unclear whether
neuroinflammation is an inciting factor or a response to neuronal
damage. However, glial activation and neuroinflammation has
been shown to precede the onset of neuron loss in many LSDs,
which strongly implies that neuroinflammation contributes
to neurodegeneration. This is further supported by several
reports, as noted in previous sections, that anti-inflammatory
agents are capable of mitigating disease progression and
improving neuronal survival. Besides the contribution of glial
cells, neurons are also capable of releasing DAMPs to signal
neuroinflammation (Thundyil and Lim, 2014). In the case of
JNCL, inclusions are primarily observed in neurons throughout
multiple brain regions (Cotman et al., 2002; Mole et al., 2005;
Burkovetskaya et al., 2014). Additional evidence to support
neuronal induction of inflammation is provided by a GD mouse
model where GlcCerase was ablated in neurons, astrocytes,
and oligodendrocytes, leaving microglia with a fully functional
GlcCerase. These mice exhibited both microglial and astrocyte
activation by postnatal day 12 (Farfel-Becker et al., 2011).
These studies have also shown glucosylceramide accumulation
primarily in cortical and thalamic neurons but not glia (Farfel-
Becker et al., 2011), suggesting that neurons have to potential
to direct inflammatory responses in LSDs and perpetuate disease
progression.
There is currently no cure for any of the LSDs. For
those that are caused by the lack of enzymatic activities,
current therapeutic approaches include enzyme replacement
therapy, which is costly and presents many challenges to
achieve therapeutic enzyme levels in the brain because the
blood-brain barrier remains intact in many instances (Bennett
and Mohan, 2013). Therefore, new approaches, such as
gene therapy, should be considered in an effort to correct
the mutation and extend the survival of patients aﬄicted
with LSDs. A better understanding of the cellular basis
of neuroinflammation as well as how neuroinflammatory
mechanisms contribute to LSD pathogenesis may enable
combinational therapeutic approaches to exert a positive impact
on disease outcome. Indeed, this approach has been successfully
employed in Krabbe Disease, another LSD with robust CNS
manifestations, where combined gene therapy and bone
marrow transplantation produces a synergistic effect on survival
compared to either therapeutic alone (Escolar et al., 2005;
Hawkins-Salsbury et al., 2011, 2015; Qin et al., 2012). However,
bone marrow transplantation has shown limited efficacy in
other LSDs, again highlighting the heterogeneity between
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different disorders and need to tailor potential therapeutics
accordingly.
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